Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases
Tóm tắt
The proteoglycan biglycan (BGN) is involved in collagen fibril assembly and its fragmentation is likely to be associated with collagen turnover during the pathogenesis of diseases which involve dysregulated extracellular matrix remodeling (ECMR), such as rheumatoid arthritis (RA) and liver fibrosis. The scope of the present study was to develop a novel enzyme-linked immunosorbent assay (ELISA) for the measurement of a MMP-9 and MMP-12-generated biglycan neo-epitope and to test its biological validity in a rat model of RA and in two rat models of liver fibrosis, chosen as models of ECMR. Biglycan was cleaved in vitro by MMP-9 and -12 and the 344′YWEVQPATFR′353 peptide (BGM) was chosen as a potential neo-epitope. A technically sound competitive ELISA for the measurement of BGM was generated and the assay was validated in a bovine cartilage explant culture (BEX), in a collagen induced model of rheumatoid arthritis (CIA) and in two different rat models of liver fibrosis: the carbon tetrachloride (CCL4)-induced fibrosis model, and the bile duct ligation (BDL) model. Significant elevation in serum BGM was found in CIA rats compared to controls, in rats treated with CCL4 for 16 weeks and 20 weeks compared to the control groups as well as in all groups of rats subject to BDL compared with sham operated groups. Furthermore, there was a significant correlation of serum BGM levels with the extent of liver fibrosis determined by the Sirius red staining of liver sections in the CCL4 model. We demonstrated that the specific tissue remodeling product of MMPs-degraded biglycan, namely the neo-epitope BGM, is correlated with pathological ECMR. This assay represents both a novel marker of ECM turnover and a potential new tool to elucidate biglycan role during the pathological processes associated with ECMR.
Tài liệu tham khảo
Cox TR, Erler JT: Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011, 4: 165-178.
Karsdal MA, Nielsen MJ, Sand JM: Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2012, 11 (2): 70-92.
Wiberg C, Hedbom E, Khairullina A: Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. J Biol Chem. 2001, 276: 18947-18952.
Schaefer L, Babelova A, Kiss E: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005, 115: 2223-2233.
Melchior-Becker A, Dai G, Ding Z: Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem. 2011, 286: 17365-17375.
Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006, 10: 76-99.
Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E: Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 2006, 25: 332-341.
Tang T, Thompson JC, Wilson PG: Decreased body fat, elevated plasma transforming growth factor-beta levels, and impaired BMP4-like signaling in biglycan-deficient mice. Connect Tissue Res. 2012, 54 (1): 5-13.
KirimLioglu H, KirimLioglu V, Yilmaz S: Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc. 2008, 40: 3574-3577.
Madala SK, Pesce JT, Ramalingam TR: Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol. 2010, 184: 3955-3963.
Hemmann S, Graf J, Roderfeld M, Roeb E: Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007, 46: 955-975.
Sondergaard BC, Henriksen K, Wulf H: Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthr Cartil. 2006, 14: 738-748.
Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B: Serum markers of liver fibrosis: combining the BIPED classification and neo-epitope approach in the development of new biomarkers. Dis Markers. 2009, 28 (1): 15-28.
Karsdal MA, Henriksen K, Leeming DJ: Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009, 14: 181-202.
Veidal SS, Vassiliadis E, Barascuk N: Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 2010, 30: 1293-1304.
Barascuk N, Veidal SS, Larsen L: A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010, 43: 899-904.
Vassiliadis E, Veidal SS, Barascuk N: Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol. 2011, 11: 6.
Veidal SS, Karsdal MA, Nawrocki A: Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair. 2011, 4: 22.
Veidal SS, Larsen DV, Chen X: MMP-mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem. 2012, 45: 541-546.
Veidal SS, Karsdal MA, Vassiliadis E: MMP mediated degradation of type VI collagen is highly associated with liver fibrosis–identification and validation of a novel biochemical marker assay. PLoS One. 2011, 6: e24753.
Hogemann B, Edel G, Schwarz K, Krech R, Kresse H: Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract. 1997, 193: 747-751.
Kolb M, Margetts PJ, Sime PJ, Gauldie J: Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol. 2001, 280: L1327-L1334.
Stokes MB, Holler S, Cui Y: Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int. 2000, 57: 487-498.
Ahmed MS, Oie E, Vinge LE: Induction of myocardial biglycan in heart failure in rats–an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovasc Res. 2003, 60: 557-568.
Bereczki E, Santha M: The role of biglycan in the heart. Connect Tissue Res. 2008, 49: 129-132.
Nastase MV, Young MF, Schaefer L: Biglycan: a multivalent proteoglycan providing structure and signals. J Histochem Cytoche. 2012, 60 (12): 963-975.
Karsdal MA, Sumer EU, Wulf H: Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum. 2007, 56: 1549-1558.
Karsdal MA, Madsen SH, Christiansen C: Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008, 10: R63.
Siebuhr AS, Wang J, Karsdal MA, Bay-Jensen A: Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen-induced arthritis. J Transl Med. 2012, 10: 195.
Leeming DJ, Byrialsen I, Jiménez W, Christiansen C, Karsdal MA: Protein fingerprinting of the extracellular matrix remodeling in a rat model of liver fibrosis - a serological evaluation. Liver Int. 2013, 33: 439-447.
Friedman SL: Liver fibrosis – from bench to bedside. J Hepatol. 2003, 38 (Suppl 1): S38-S53.
Weiler-Normann C, Herkel J, Lohse AW: Mouse models of liver fibrosis. Z Gastroenterol. 2007, 45: 43-50.
Combet C, Blanchet C, Geourjon C, Deleage G: NPS@: network protein sequence analysis. Trends Biochem Sci. 2000, 25: 147-150.
Schaller S, Henriksen K, Hoegh-Andersen P: In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol. 2005, 3: 553-580.
Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G: Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair. 2011, 4: 19.
Clarià J, Jimenez W: Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis Diagnosis and Treatment . Edited by: Arroyo V, Ginès P, Rodés J, Schrier RW. 2005, Malden, MA: Blackwell Science Inc, 379-396.
Munoz-Luque J, Ros J, Fernandez-Varo G: Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2008, 324: 475-483.